Related Experiment Video
Updated: Apr 24, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Virologic and genetic evaluation of vemurafenib-induced skin cancers
Emi Dika1, Annalisa Patrizi, Annalisa Altimari
1Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna , Bologna , Italy .
Abstract:
We describe the occurrence of a giant squamous cell carcinoma in a patient receiving vemurafenib for the treatment of late melanoma mestastases. Although the development of keratoacanthomas and squamous cell carcinomas (SCC) has been described during vemurafenib therapy, most of the reported cases are treated with surgical excision. In the present case, SCC regressed after drug withdrawal.
Insights
Vemurafenib therapy for advanced melanoma can cause giant squamous cell carcinoma (SCC). In one case, SCC regressed after discontinuing vemurafenib, suggesting a link between the drug and tumor development.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Vemurafenib is a targeted therapy used for advanced melanoma.
- Cutaneous side effects, including squamous cell carcinoma (SCC) and keratoacanthomas, are known complications of vemurafenib treatment.
Observation:
- A patient undergoing vemurafenib therapy for metastatic melanoma developed a giant squamous cell carcinoma.
- This specific case involved a large SCC, a known but less common side effect of vemurafenib.
Findings:
- While SCCs associated with vemurafenib are typically managed surgically, this giant SCC showed complete regression upon cessation of the drug.
- This observation supports a direct causal relationship between vemurafenib and the development of SCC in some patients.
Implications:
- Discontinuation of vemurafenib may be a viable treatment strategy for drug-induced SCC, potentially avoiding surgical intervention.
- Further research is warranted to understand the mechanisms underlying vemurafenib-induced SCC and to optimize management strategies for melanoma patients experiencing these side effects.
More Related Videos
11:02The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
Published on: August 3, 2011
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Mechanisms of Retrovirus-induced Cancers
Mutagenicity and Carcinogenicity
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...